PharmaSGP Holding SE (ETR:PSG)

Market Cap	308.54M
Revenue (ttm)	118.84M
Net Income (ttm)	19.54M
Shares Out	11.51M
EPS (ttm)	1.65
PE Ratio	16.29
Forward PE	11.36
Dividend	0.51 (1.89%)
Ex-Dividend Date	Jun 26, 2025

Volume	977
Average Volume	1,675
Open	27.00
Previous Close	27.00
Day's Range	26.80 - 27.00
52-Week Range	19.00 - 30.00
Beta	-0.08
RSI	59.92
Earnings Date	Apr 29, 2025

About PharmaSGP Holding SE

PharmaSGP Holding SE manufactures and sells over-the-counter drugs and other healthcare products in Germany. The company’s pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage creams for the treatment of various pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Revitensin, a drug for the treatment of hair loss; Dorisol for neuralgia (nerve ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2012
• Employees: 91
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: PSG

Financial Performance

In 2024, PharmaSGP Holding SE's revenue was 118.84 million, an increase of 17.55% compared to the previous year's 101.10 million. Earnings were 19.54 million, an increase of 19.14%.